SYM FINANCIAL Corp Sells 397 Shares of Incyte Corporation $INCY

SYM FINANCIAL Corp lessened its stake in shares of Incyte Corporation (NASDAQ:INCY) by 5.7% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 6,565 shares of the biopharmaceutical company’s stock after selling 397 shares during the period. SYM FINANCIAL Corp’s holdings in Incyte were worth $447,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Czech National Bank raised its stake in shares of Incyte by 6.4% during the 2nd quarter. Czech National Bank now owns 39,271 shares of the biopharmaceutical company’s stock worth $2,674,000 after purchasing an additional 2,378 shares in the last quarter. Principal Financial Group Inc. raised its position in Incyte by 0.7% during the first quarter. Principal Financial Group Inc. now owns 213,947 shares of the biopharmaceutical company’s stock worth $12,954,000 after acquiring an additional 1,419 shares in the last quarter. Amalgamated Bank raised its position in Incyte by 1.9% during the first quarter. Amalgamated Bank now owns 31,551 shares of the biopharmaceutical company’s stock worth $1,910,000 after acquiring an additional 591 shares in the last quarter. OMNI 360 Wealth Inc. bought a new stake in Incyte during the second quarter worth $310,000. Finally, Poinciana Advisors Group LLC bought a new stake in Incyte during the second quarter worth $229,000. Institutional investors own 96.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on INCY shares. Wells Fargo & Company raised shares of Incyte from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $67.00 to $89.00 in a report on Wednesday, August 6th. JPMorgan Chase & Co. lifted their target price on Incyte from $73.00 to $89.00 and gave the stock a “neutral” rating in a report on Thursday, October 9th. Barclays initiated coverage on Incyte in a report on Friday, August 1st. They set an “overweight” rating and a $90.00 target price for the company. Guggenheim reaffirmed a “neutral” rating on shares of Incyte in a research report on Friday, September 19th. Finally, UBS Group reaffirmed a “neutral” rating and set a $68.00 target price (up from $62.00) on shares of Incyte in a report on Wednesday, July 30th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Incyte has an average rating of “Hold” and a consensus price target of $84.79.

Incyte Stock Performance

Shares of NASDAQ:INCY opened at $93.08 on Tuesday. Incyte Corporation has a 1 year low of $53.56 and a 1 year high of $93.17. The company’s 50 day simple moving average is $85.81 and its 200 day simple moving average is $73.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.85 and a quick ratio of 2.78. The stock has a market capitalization of $18.18 billion, a price-to-earnings ratio of 21.15, a price-to-earnings-growth ratio of 0.71 and a beta of 0.73.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.